Immuno-Oncology
Leadership
Chair
Bernardo Rapoport, MD, MMED, South Africa
Vice-Chair
Mario Lacouture, MD
USA
Immuno-Oncology is a subgroup of the Neutropenia, Infection & Myelosuppression Study Group
How to Join
To join a subgroup, you must be a MASCC member and a member of the parent study group. The parent study group of the Immuno-Oncology Subgroup is the Neutropenia, Infection & Myelosuppression Study Group.
- Log in to your member account by clicking “Member Login” in the top right of the screen (on mobile devices you will need to first open the mobile menu).
- Enter your username and password and then click on “Manage My Account/Profile”.
- Scroll down to your profile data and select “Edit”.
- Then select this subgroup as one of your subgroup selections. Click SAVE.
Have Questions?
Mission and Goals
The emergence of immune checkpoint inhibitors (ICIs) that target the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein-1/ ligand 1 (PD-1/PD-L1) pathway has significantly improved outcomes for patients with a variety of malignancies. By blocking the inhibitory signaling pathway of T-cells, ICIs are associated with a diverse spectrum of immune-related adverse events (irAEs) involving multiple organ systems. This new subgroup on Immuno-Oncology (IO) comprises study group members interested in organ systems from disciplines related to immunotherapy-related events, including, but not limited to, gastroenterology, dermatology, neurology, hematology, rheumatology, endocrinology, nephrology, and emergency medicine.
The goal of the subgroup is to create a multidisciplinary team that brings together the best information and ideas about this new and growing field. Aims are to develop educational sessions at MASCC Annual Meetings and research projects involving MASCC members. The subgroup will also serve as a resource for information and contacts with companies involved in immunotherapies that might help fund MASCC projects. The IO subgroup will meet every year at the MASCC Annual Meeting, beginning in 2019. The first project of the subgroup is to develop position papers for the management of corticosteroid resistant or refractory adverse events. Future projects will be developed on the basis of members’ interests.
